To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 Diabetes

A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Compare the Effects of 12 Weeks Treatment With Vildagliptin 50 mg Bid to Voglibose 0.2 mg Tid in Patients With Type 2 Diabetes

This study is designed to evaluate the efficacy, safety and tolerability of vildagliptin compared to voglibose in patients with type 2 diabetes. Please note this study is not being conducted in the United States.

Inclusion Criteria:

• Diagnosis as Type 2 Diabetes
• Patients who have been placed on dietary therapy/exercise therapy, without achievement of glycemic control
• Outpatients

Exclusion Criteria:

• Type 1 diabetes mellitus, diabetes that is a result of pancreatic injury, or secondary forms of diabetes
• Significant heart diseases
• Significant diabetic complications

Other protocol-defined inclusion/exclusion criteria may apply